D. E. Shaw & Co., Inc. Adverum Biotechnologies, Inc. Transaction History

D. E. Shaw & Co., Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $238,482 - $345,605	-24,236 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $249,630 - $524,467	24,236 New	24,236 $250,000
Q2 2020 Aug 14, 2020	SELL	$8.53 - $25.64 $516,201 - $1.55 Million	-60,516 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $1.04 Million - $2.13 Million	-130,648 Reduced 68.34%	60,516 $592,000
Q4 2019 Feb 14, 2020	SELL	$5.12 - $12.22 $195,901 - $467,561	-38,262 Reduced 16.68%	191,164 $2.2 Million
Q3 2019 Nov 14, 2019	BUY	$5.24 - $15.89 $504,695 - $1.53 Million	96,316 Added 72.36%	229,426 $1.25 Million
Q2 2019 Aug 14, 2019	BUY	$5.1 - $11.89 $546,771 - $1.27 Million	107,210 Added 413.94%	133,110 $1.58 Million
Q1 2019 May 15, 2019	SELL	$3.03 - $6.02 $2,121 - $4,214	-700 Reduced 2.63%	25,900 $136,000
Q4 2018 Feb 14, 2019	SELL	$2.87 - $5.92 $112,650 - $232,365	-39,251 Reduced 59.61%	26,600 $84,000
Q3 2018 Nov 14, 2018	SELL	$4.5 - $7.6 $97,191 - $164,144	-21,598 Reduced 24.7%	65,851 $398,000
Q2 2018 Aug 14, 2018	BUY	$5.3 - $6.9 $290,053 - $377,616	54,727 Added 167.25%	87,449 $463,000
Q1 2018 May 15, 2018	BUY	$3.65 - $7.95 $119,435 - $260,139	32,722 New	32,722 $190,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $449M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.